Clinical Data

Fierce Pharma

Sarepta, despite key trial flop, will seek full nod for DMD meds

Sarepta’s Vyondys 53 and Amondys 45 failed to show a statistically significant difference versus placebo on a key measurement of DMD patient mobility.

Angus Liu Nov 4, 2025 7:56am

Takeda drops AZ-partnered neurological program after ph. 2 fail

Oct 30, 2025 9:25am

Novartis’ phase 3 wins in Sjögren's see high placebo effect

Oct 29, 2025 12:03pm

Metallic arrow symbols illuminated by blue and magenta lights forming a graph on blue and magenta background

Kyverna links CAR-T to autoimmune improvements in small trial

Oct 29, 2025 10:00am

BridgeBio's calcium deficiency candidate scores phase 3 win

Oct 29, 2025 7:00am

Heart on futuristic podium with neon lighting

Jupiter Endovascular's catheter platform shows positive results

Oct 28, 2025 10:00am